| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2773 |
| Trial ID | NCT05020678 |
| Disease | Non-Hodgkin's Lymphoma | B-Cell Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Mantle Cell Lymphoma | Large B-Cell Lymphoma | Small Lymphocytic Lymphoma | Waldenstrom Macroglobulinemia | Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-NK cell |
| Treatment | NKX019 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers |
| Year | 2021 |
| Country | United States |
| Company sponsor | Nkarta Inc. |
| Other ID(s) | NKX019-101 |
| Cohort 1 | |||||||||||
|
|||||||||||